Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Prevention of cytosolic IAPs degradation: a potential pharmacological target in Huntington's Disease.

Pharmacological research - 1 Aug 2005

Goffredo Donato, Rigamonti Dorotea, Zuccato Chiara, Tartari Marzia, Valenza Marta, Cattaneo Elena

Abstract excerpt

Huntington's Disease (HD) is a neurodegenerative disorder caused by an abnormally expanded polyglutamine trait in the amino-terminal region of huntingtin. Pathogenic mechanisms involve a gained toxicity of mutant huntingtin and a potentially reduced neuroprotective function of the wild-type allele. Among the molecular abnormalities reported, HD cells are characterized by the presence of aggregates,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Apoptosis Regulatory Proteins
Share to Cyclosporine

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytosol

Share to Huntingtin Protein

Share to Huntington Disease

Share to Inhibitor of Apoptosis Proteins

Share to Pyrimidinones

Share to X-Linked Inhibitor of Apoptosis Protein

Source

Identifiers

PMID: 15967379
DOI: 10.1016/j.phrs.2005.01.006

Genes

HTRA2
DIABLO
XIAP

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Prevention of cytosolic IAPs degradation: a potential pharmacological target in Huntington's Disease.PMID 15967379Read ↗

Potential of Therapeutic Small Molecules in Apoptosis Regulation in the Treatment of Neurodegenerative Diseases: An Updated ReviewSemantic proximity Read ↗

Inactivation of Apaf1 reduces the formation of mutant huntingtin-dependent aggregates and cell death.Semantic proximity Read ↗

Downregulation of NF-kappaB signaling by mutant huntingtin proteins induces oxidative stress and cell death.Semantic proximity Read ↗

Novel survivin mutant protects differentiated SK-N-SH human neuroblastoma cells from activated T-cell neurotoxicity.Semantic proximity Read ↗

Class IIA HDACs in the regulation of neurodegenerationSemantic proximity Read ↗

The S. cerevisiae HtrA-like protein Nma111p is a nuclear serine protease that mediates yeast apoptosis.Semantic proximity Read ↗

Pharmacologic inhibition of MIF nuclease: A new treatment paradigm to treat cell deathSemantic proximity Read ↗

Insulin-like growth factor 2 (IGF2) protects against Huntington’s disease through the extracellular disposal of protein aggregatesSemantic proximity Read ↗

Laquinimod decreases Bax expression and reduces caspase-6 activation in neurons.Semantic proximity Read ↗

Recruitment of mitochondria into apoptotic signaling correlates with the presence of inclusions formed by amyotrophic lateral sclerosis-associated SOD1 mutations.Semantic proximity Read ↗

Omi/HtrA2 catalytic cleavage of inhibitor of apoptosis (IAP) irreversibly inactivates IAPs and facilitates caspase activity in apoptosis.Semantic proximity Read ↗

Blocking acid-sensing ion channel 1 alleviates Huntington's disease pathology via an ubiquitin-proteasome system-dependent mechanism.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.